PsiOxus raises $34M for cancer vax studies; Merck KGaA threatens to jerk R&D unless Portugal pays up;

 @FierceBiotech: Australian ‪cancer‬ ‪biotech‬ spin-out Alchemia pitches $60M ‪IPO‬ stateside. More | Follow @FierceBiotech

 @JohnCFierce: Israel's RDD Pharma raised a bit more than $7M from Orbimed to develop drugs delivered up the anal canal. More | Follow @JohnCFierce

 @RyanMFierce: Biotech‬ Genkyotex nails down $26M to fund drug for diabetic kidney disease. More | Follow @RyanMFierce

> London-based PsiOxus Therapeutics has rounded up $34 million for its Series B. The round included equal investments from existing investors Imperial Innovations Group and Invesco Perpetual together with new investments by SR One and Lundbeckfond Ventures. The money is earmarked for ColoAd1, an oncolytic vaccine, which is being put through Phase I and Phase II clinical trials for colorectal and other forms of cancer. PsiOxus was formed to commercialize technologies discovered in U.K. universities. Release

> Merck KGaA has found a novel way to add some leverage to back its demand that Portugal pay up for its drugs. The European pharma company is threatening to end its R&D work in the country unless the money starts to flow. A number of pharma companies have taken an increasingly hard line on drug payments as several southern European countries work through a severe economic crisis. Story

> Israel's RDD Pharma raised $7.15 million from OrbiMed Advisors to back its drug candidates designed to be delivered through the anal canal. Story

> Galenica reports that PA21 met primary and secondary endpoints in a late-stage study of hyperphosphatemia in patients with chronic kidney disease. Release

> Lux Biosciences has completed patient enrollment in its Phase III clinical study of Luveniq (oral voclosporin) for non-infectious uveitis. Lux anticipates that data from the study will be available early in the first quarter of 2013. Release

Pharma News

 @FiercePharma: ‪Merck‬ KGaA says it'll stop investing in R&D in Portugal if drug bills don't get paid. More | Follow @FiercePharma

> Lilly could net $1.5B-plus from Cymbalta extension. Story

> Med students protest as Massachusetts relaxes pharma gift ban. Article

> Is it or isn't it? Celgene said to mull bid for HGS, or not. More

> Forest urges investors to reject Icahn's board nominees. News

Medical Device News

@FierceMedDev: Luminex snaps up diagnostics firm GenturaDx for $50M in cash. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Stryker is recalling two all-metal hip implants after reports of corrosion and failure. More | Follow @DamianFierce

> Qiagen gets FDA nod for colorectal cancer Dx. News

> Timeline: The industry gets serious about device hacking. Editor's Corner

> Cook snags 510(k) for colonic stent. More

> Devicemaker CartiHeal pulls in $10M financing round. Article

Biotech IT News

> Mount Sinai Medical Center, Cloudera embrace Big Data in genomics. Story

> Voice software offers potential tool for clinical trials. Article

> ERT scoops up Invivodata for ePRO clinical trials tech. More

> Mytrus aligns leadership for at-home clinical trials biz. News

And Finally… Investigators at Stanford say they have discovered a new molecule that promises to starve lung cancer. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.